Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 8/20 | 0.62 |
| ▸ | HTR4 | Q13639 | 8/20 | 0.62 |
| ▸ | PARP1 | P09874 | 2/20 | 0.56 |
| ▸ | PBK | Q96KB5 | 2/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | EP300 | Q09472 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL829207 | 1.00 | HTR3A (0.62) | HTR3AHTR4PARP1PBKCHRM1 | |
| SCHEMBL828472 | 0.92 | HTR3A (0.65) | HTR3AHTR4PARP1 | |
| SCHEMBL29397821 | 0.92 | HTR3A (0.65) | HTR3AHTR4PARP1 | |
| SCHEMBL4244377 | 0.84 | PBK (0.53) | HTR3AHTR4PARP1PBKCHRM1 | |
| SCHEMBL828936 | 0.83 | HTR4 (0.68) | HTR3AHTR4PARP1PBKCHRM1 | |
| SCHEMBL29397140 | 0.83 | HTR4 (0.68) | HTR3AHTR4PARP1PBKCHRM1 | |
| SCHEMBL828769 | 0.83 | HTR3A (0.62) | HTR3AHTR4PARP1 | |
| SCHEMBL4244372 | 0.82 | PARP1 (0.62) | PARP1PBKCHRM1 | |
| SCHEMBL829424 | 0.80 | HTR4 (0.76) | HTR3AHTR4PARP1 | |
| Trifluoroacetic Acid SCHEMBL829123 | 0.79 | HTR4 (0.61) | HTR3AHTR4PARP1PBKCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220274957-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-01 | — | — | US | disclosed |
| US-11254655-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254655-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR1A, HTR5A | HTR3A 18/4885HTR4 1/4885PARP1 1181/4885 |
| US-20220274957-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR1A, HTR5A | HTR3A 18/4885HTR4 1/4885PARP1 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.